NASDAQ:GMAB Genmab A/S (GMAB) Stock Price, News & Analysis $27.21 +1.53 (+5.96%) Closing price 04:00 PM EasternExtended Trading$27.22 +0.01 (+0.04%) As of 05:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Genmab A/S Stock (NASDAQ:GMAB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Genmab A/S alerts:Sign Up Key Stats Today's Range$26.09▼$27.3750-Day Range$25.10▼$29.3052-Week Range$20.23▼$35.43Volume5.20 million shsAverage Volume1.85 million shsMarket Capitalization$16.97 billionP/E Ratio20.61Dividend YieldN/APrice Target$39.07Consensus RatingModerate Buy Company Overview Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development. Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners. Its most notable marketed therapies include daratumumab (commercialized as Darzalex®) for multiple myeloma, developed with Johnson & Johnson, and isatuximab (Sarclisa®) for relapsed or refractory multiple myeloma, in partnership with Sanofi. In addition to these approved treatments, Genmab is advancing a pipeline of bispecific and multispecific antibody candidates designed to engage the immune system in novel ways, including its DuoBody® and HexaBody® platforms. Beyond its core product assets, Genmab maintains strategic alliances across North America, Europe and Asia, leveraging the commercial reach of its partners to bring therapies to patients worldwide. The company operates research facilities in Copenhagen and Utrecht, along with offices in Princeton, New Jersey, to support clinical and regulatory activities in the United States. Genmab’s leadership team, led by President and Chief Executive Officer Jan van de Winkel, PhD, comprises seasoned executives and scientific experts committed to driving innovation in immuno-oncology. With a focus on sustainable growth, Genmab continues to expand its pipeline and explore new antibody formats aimed at improving response rates and durability of remission for cancer patients. The company’s ongoing clinical trials span multiple tumor types and combination regimens, underscoring its mission to translate cutting-edge antibody science into transformative cancer therapies.AI Generated. May Contain Errors. Read More Genmab A/S Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks83rd Percentile Overall ScoreGMAB MarketRank™: Genmab A/S scored higher than 83% of companies evaluated by MarketBeat, and ranked 105th out of 851 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingGenmab A/S has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 2 strong buy ratings, 7 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialGenmab A/S has a consensus price target of $39.07, representing about 43.1% upside from its current price of $27.31.Amount of Analyst CoverageGenmab A/S has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Genmab A/S's stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth38.66% Earnings GrowthEarnings for Genmab A/S are expected to grow by 38.66% in the coming year, from $1.19 to $1.65 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Genmab A/S is 20.67, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.51.Price to Earnings Ratio vs. SectorThe P/E ratio of Genmab A/S is 20.67, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 20.71.Price to Earnings Growth RatioGenmab A/S has a PEG Ratio of 1.54. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioGenmab A/S has a P/B Ratio of 3.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Genmab A/S's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted1.38% of the float of Genmab A/S has been sold short.Short Interest Ratio / Days to CoverGenmab A/S has a short interest ratio ("days to cover") of 5.17.Change versus previous monthShort interest in Genmab A/S has recently increased by 7.20%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGenmab A/S does not currently pay a dividend.Dividend GrowthGenmab A/S does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.41 News SentimentGenmab A/S has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Genmab A/S this week, compared to 6 articles on an average week.Search Interest9 people have searched for GMAB on MarketBeat in the last 30 days. This is an increase of 350% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Genmab A/S to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Genmab A/S insiders have not sold or bought any company stock.Percentage Held by Insiders1.54% of the stock of Genmab A/S is held by insiders.Percentage Held by Institutions7.07% of the stock of Genmab A/S is held by institutions.Read more about Genmab A/S's insider trading history. Receive GMAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GMAB Stock News HeadlinesGenmab (CPSE:GMAB) Valuation Check After Recent Share Price Softness And 24.6% Undervaluation EstimateMay 17 at 1:49 PM | finance.yahoo.comGenmab A/S (GMAB) Q1 2026 Earnings Call TranscriptMay 14, 2026 | seekingalpha.comA 17-year investing experiment investigated in DublinPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.May 20 at 1:00 AM | Porter & Company (Ad)Genmab A/S: Capital Increase in Genmab as a Result of Employee Warrant ExerciseMay 13, 2026 | finanznachrichten.de5 Most Promising Biotech Stocks to Buy NowMay 12, 2026 | insidermonkey.comCapital Increase in Genmab as a Result of Employee Warrant ExerciseMay 12, 2026 | globenewswire.comGenmab A/S 2026 Q1 - Results - Earnings Call PresentationMay 10, 2026 | seekingalpha.comGenmab A/S (NASDAQ:GMAB) Shares Gap Down - Should You Sell?May 10, 2026 | americanbankingnews.comSee More Headlines GMAB Stock Analysis - Frequently Asked Questions How have GMAB shares performed this year? Genmab A/S's stock was trading at $30.80 at the beginning of 2026. Since then, GMAB shares have decreased by 11.3% and is now trading at $27.3050. How were Genmab A/S's earnings last quarter? Genmab A/S Sponsored ADR (NASDAQ:GMAB) announced its earnings results on Wednesday, February, 18th. The company reported $0.05 earnings per share for the quarter, missing analysts' consensus estimates of $0.46 by $0.41. The firm earned $1.06 billion during the quarter, compared to analyst estimates of $1.06 billion. Genmab A/S had a trailing twelve-month return on equity of 15.34% and a net margin of 21.05%. Read the conference call transcript. When did Genmab A/S IPO? Genmab A/S (GMAB) raised $503 million in an IPO on Thursday, July 18th 2019. The company issued 27,800,000 shares at a price of $18.11 per share. BofA Merrill Lynch, Morgan Stanley and Jefferies served as the underwriters for the IPO and Guggenheim Securities and RBC Capital Markets were co-managers. Who are Genmab A/S's major shareholders? Genmab A/S's top institutional investors include Arrowstreet Capital Limited Partnership (0.80%), Renaissance Technologies LLC (0.71%), First Trust Advisors LP (0.39%) and Pictet Asset Management Holding SA (0.17%). How do I buy shares of Genmab A/S? Shares of GMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Genmab A/S own? Based on aggregate information from My MarketBeat watchlists, some other companies that Genmab A/S investors own include NVIDIA (NVDA), Medtronic (MDT), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Meta Platforms (META), Tesla (TSLA) and Datadog (DDOG). Company Calendar Last Earnings2/18/2026Today5/20/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 GMAB's financial health is in the Red zone, according to TradeSmith. GMAB has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GMAB CIK1434265 Webwww.genmab.com Phone(457) 020-2728FaxN/AEmployees3,029Year Founded1999Price Target and Rating Average Price Target for Genmab A/S$39.07 High Price Target$48.00 Low Price Target$32.00 Potential Upside/Downside+43.6%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)$1.32 Trailing P/E Ratio20.61 Forward P/E Ratio22.87 P/E Growth1.54Net Income$963 million Net Margins21.05% Pretax Margin26.51% Return on Equity15.34% Return on Assets8.94% Debt Debt-to-Equity Ratio0.87 Current Ratio2.18 Quick Ratio2.17 Sales & Book Value Annual Sales$3.72 billion Price / Sales4.56 Cash Flow$1.66 per share Price / Cash Flow16.38 Book Value$9.11 per share Price / Book2.99Miscellaneous Outstanding Shares623,510,000Free Float613,905,000Market Cap$16.97 billion OptionableOptionable Beta0.86 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:GMAB) was last updated on 5/20/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredAre we ignoring the same signal Wall Street ignored in 1929?In 1929, Irving Weiss spotted a systemic crisis hiding beneath record highs and shorted the market - turning $...Weiss Ratings | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredTrump Is Eyeing the Biggest Monetary Shift Since NixonOn August 15, 1971, Nixon ended the Bretton Woods agreement and untethered the dollar from gold. Since that ni...Americas Gold Company | SponsoredOne page of the SpaceX S-1 will move this stock overnightWhen SpaceX files its S-1 in June, the SEC will require full disclosure of operating expenses - including powe...Behind the Markets | SponsoredThe Death of the Nasdaq?The Death of the Nasdaq? Wall Street legend Marc Chaikin's award-winning system turned bearish on software ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genmab A/S Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Genmab A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
